Literature DB >> 25638249

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

Julie A Johnson1, Issam S Hamadeh2, Taimour Y Langaee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25638249     DOI： 10.1093/jnci/dju437

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

Review 1.  Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Authors:  Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton
Journal:  Am J Epidemiol       Date:  2016-12-17       Impact factor: 4.897

2.  Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.

Authors:  Thomas P Ahern; Lindsay J Collin; James W Baurley; Anders Kjærsgaard; Rebecca Nash; Maret L Maliniak; Per Damkier; Michael E Zwick; R Benjamin Isett; Peer M Christiansen; Bent Ejlertsen; Kristina L Lauridsen; Kristina B Christensen; Rebecca A Silliman; Henrik Toft Sørensen; Trine Tramm; Stephen Hamilton-Dutoit; Timothy L Lash; Deirdre Cronin-Fenton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Authors:  Matthew P Goetz; Katrin Sangkuhl; Henk-Jan Guchelaar; Matthias Schwab; Michael Province; Michelle Whirl-Carrillo; W Fraser Symmans; Howard L McLeod; Mark J Ratain; Hitoshi Zembutsu; Andrea Gaedigk; Ron H van Schaik; James N Ingle; Kelly E Caudle; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2018-01-31       Impact factor: 6.875

Review 4.  Moving Pharmacogenetics Into Practice: It's All About the Evidence!

Authors:  Jasmine A Luzum; Natasha Petry; Annette K Taylor; Sara L Van Driest; Henry M Dunnenberger; Larisa H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2021-07-07       Impact factor: 6.903

5.  CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.

Authors:  Per Damkier; Anders Kjærsgaard; Kimberly A Barker; Deidre Cronin-Fenton; Anatasha Crawford; Ylva Hellberg; Emilius A M Janssen; Carl Langefeld; Thomas P Ahern; Timothy L Lash
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.